Parkinson's disease: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
| Line 11: | Line 11: | ||
==Clinical Features== | ==Clinical Features== | ||
===TRAP mnemonic=== | ===TRAP mnemonic=== | ||
*'''T'''remor (resting) | *[[tremor|'''T'''remor]] (resting) | ||
**Initially is unilateral tremor of upper extremity, especially finger and thumb ("pill rolling") | **Initially is unilateral tremor of upper extremity, especially finger and thumb ("pill rolling") | ||
**Dissipates when intentional movement is performed | **Dissipates when intentional movement is performed | ||
| Line 28: | Line 28: | ||
==Management== | ==Management== | ||
''Initiation of or modifications in medications should be made in conjunction with neurologist'' | |||
*Dopamine agonists | *Dopamine agonists | ||
**[[Levodopa]] and [[carbidopa]] (peripheral decarboxylase inhibitor) = gold standard | **[[Levodopa]] and [[carbidopa]] (peripheral decarboxylase inhibitor) = gold standard | ||
**[[Pramipexole]] (Mirapex) | **[[Pramipexole]] (Mirapex) | ||
**Ropinirole (Requip) | **Ropinirole (Requip) | ||
* | *[[Anticholinergics]] | ||
**[[Benztropine]] - caution in acute psychosis | **[[Benztropine]] - caution in acute psychosis | ||
*Monoamine oxidase inhibitor - blocks DA reuptake | *Monoamine oxidase inhibitor - blocks DA reuptake | ||
**Selegiline (Eldepryl) | **Selegiline (Eldepryl) | ||
**Rasagiline (Azilect) | **Rasagiline (Azilect) | ||
*Agents for psychotic symptoms, hallucinations | *Agents for [[psychosis|psychotic symptoms]], [[hallucinations]] | ||
**Pimavanserin (Nuplazaid) - serotonin inverse agonist (not anti-dopamine), FDA approved in 2016<ref>FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. April 29, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm.</ref> | **Pimavanserin (Nuplazaid) - serotonin inverse agonist (not anti-dopamine), FDA approved in 2016<ref>FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. April 29, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm.</ref> | ||
**Avoid antidopaminergic drugs if possible (expect worsening motor symptoms), but commonly used agents: | **Avoid antidopaminergic drugs if possible (expect worsening motor symptoms), but commonly used agents: | ||
Revision as of 04:25, 3 October 2019
Background
- Extrapyramidal movement disorder associated with reduced dopaminergic receptors in substantia nigra
- Most common presentations to the ED[1]:
- Infectious ~32%
- Trauma ~28%
- Cardiovascular ~15%
- Cerebrovascular ~12%
- GI ~7%
- Electrolyte abnormalities 6%
Clinical Features
TRAP mnemonic
- Tremor (resting)
- Initially is unilateral tremor of upper extremity, especially finger and thumb ("pill rolling")
- Dissipates when intentional movement is performed
- Rigidity (cogwheel)
- Elicited by causing passive movement of limb through full range of motion
- Akinesia
- Slowness of voluntary movement
- Posture/equilibrium impairment
- Impaired ability to turn or change direction while walking
Differential Diagnosis
Dementia
- Degenerative
- Alzheimer's disease
- Huntington's disease
- Parkinson's disease
- Vascular
- Multiple infarcts
- Hypoperfusion (MI, profound hypotension)
- Subdural hematoma
- SAH
- Infectious
- Meningitis (sequelae of bacterial, fungal, or tubercular)
- Neurosyphilis
- Viral encephalitis (HSV, HIV), Creutzfeldt-Jakob disease
- Inflammatory
- SLE
- Demyelinating disease (e.g. multiple sclerosis)
- Neoplastic
- Primary brain tumor / metastatic disease
- Carcinomatous meningitis
- Paraneoplastic syndromes
- Traumatic
- Toxic
- ETOH
- Meds (anticholinergics, polypharmacy)
- Metabolic
- Psychiatric
- Depression (pseudodementia)
- Hydrocephalic
- Normal pressure hydrocephalus (communicating hydrocephalus)
- Noncommunicating hydrocephalus
Evaluation
- Consider mini mental status exam
Management
Initiation of or modifications in medications should be made in conjunction with neurologist
- Dopamine agonists
- Levodopa and carbidopa (peripheral decarboxylase inhibitor) = gold standard
- Pramipexole (Mirapex)
- Ropinirole (Requip)
- Anticholinergics
- Benztropine - caution in acute psychosis
- Monoamine oxidase inhibitor - blocks DA reuptake
- Selegiline (Eldepryl)
- Rasagiline (Azilect)
- Agents for psychotic symptoms, hallucinations
- Pimavanserin (Nuplazaid) - serotonin inverse agonist (not anti-dopamine), FDA approved in 2016[2]
- Avoid antidopaminergic drugs if possible (expect worsening motor symptoms), but commonly used agents:
- Others:
- Rivastigmine
- Citalopram in depressed patients
Disposition
- Usually treated as outpatient
- Admit according to presentation
See Also
References
- ↑ Guneysel O et al. Parkinson’s disease and the frequent reasons for emergency admission. Neuropsychiatr Dis Treat. 2008 Aug; 4(4): 711–714.
- ↑ FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease. April 29, 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm.